| NCT ID | NCT06031714 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Venous Ulcer |
| Study Type | INTERVENTIONAL |
| Enrollment | 160 participants |
| Start Date | 2024-02-06 |
| Primary Completion | 2026-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 160 participants in total. It began in 2024-02-06 with a primary completion date of 2026-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to describe the transcriptomic profile of foetal cells in post-partum and more specifically to determine which chemokine receptors are overexpressed in foetal cells in post-partum women with wounds To do so, the investigators will isolate foetal cells from the peripheral blood of healthy controls post partum women as well as from post partum women with skin ulcers and then perform RNA sequencing.
Eligibility Criteria
Inclusion Criteria: Common criteria : * Adult women, * Post-partum: having been pregnant for any length of time, * Having signed a free and informed consent form, * Primiparous or multiparous, * Affiliated to a health insurance Patients : \- Patients with a venous, diabetic or sickle cell ulcer, or mixed ulcer Control group patients : * Volunteers, * Age-matched, * Without skin ulcers. There are no specific criteria for children. Exclusion Criteria: * Minors (for patients) * Under court protection, curatorship, guardianship (for patients) * Immunocompromised patients for any reason whatsoever * Refusal of consent * Refusal of blood and/or saliva samples for themselves or a member of their family
Contact & Investigator
Sélim ARACTINGI, MD, PHD
STUDY DIRECTOR
Dermatology unit, Cochin Hospital - APHP
Frequently Asked Questions
Who can join the NCT06031714 clinical trial?
This trial is open to participants of all sexes, studying Venous Ulcer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06031714 currently recruiting?
Yes, NCT06031714 is actively recruiting participants. Contact the research team at selim.aractingi@aphp.fr for enrollment information.
Where is the NCT06031714 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT06031714 clinical trial?
NCT06031714 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Sélim ARACTINGI, MD, PHD at Dermatology unit, Cochin Hospital - APHP. The trial plans to enroll 160 participants.